1/4-Sustaining Remission of Psychotic Depression
Description: This research will focus on psychotic depression (PD), one of the most severe, disabling, and lethal psychiatric disorders. The proposed study will address a question of profound clinical importance: what are the risks versus benefits of continuing treatment with antipsychotic medication, once an episode of PD has responded to combined antidepressant and antipsychotic pharmacotherapy? This randomized, placebo-controlled trial will assess whether continuation treatment with the atypical antipsychotic olanzapine, when given in combination with the antidepressant sertraline, prevents relapse of remitted PD; it will also assess the risks of this treatment with respect to weight gain and metabolic disturbance, side effects that have considerable public health significance.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2002-09-06
End date: 2018-03-31
Investigator: GEORGE S ALEXOPOULOS (lead)
Institutions: Weill Cornell Medicine, WEILL MEDICAL COLL OF CORNELL UNIV
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Funded outputs count: 39
Funder award ID: U01MH062518
OpenAlex ID: G2539926786
